Immatics

Immatics is a German cancer immunotherapy developer dedicated to discovering and developing T cell-redirecting immunotherapies for the treatment of cancer. It employs cellular therapies and bispecific TCR molecule technologies to redirect immunotherapy against tumor targets validated by XPRESIDENT.